Evidence map›Paper›PMID 37904956›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Dynamics of SARS-CoV-2 Seroprevalence in a Large US population Over a Period of 12 Months.

Maria Karkanitsa, Yan Li, Shannon Valenti, Jacquelyn Spathies, Sophie Kelly, Sally Hunsberger, Laura Yee, Jennifer A Croker, Jing Wang, Andrea Lucia Alfonso and 31 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 10 institutions in 2 countries.

Maria KarkanitsaSection on Immunoengineering, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda MD 20894.
Yan LiJoint Program in Survey Methodology, Department of Epidemiology and Biostatistics, University of Maryland College Park, College Park, MD 20742.
Shannon ValentiClinical and Translational Science Institute (CTSI), University of Pittsburgh, Pittsburgh, PA 15213.
Jacquelyn SpathiesTrans-NIH Shared Resource on Biomedical Engineering and Physical Science (BEPS), NIBIB, NIH, Bethesda MD 20894.
Sophie KellyTrans-NIH Shared Resource on Biomedical Engineering and Physical Science (BEPS), NIBIB, NIH, Bethesda MD 20894.
Sally HunsbergerBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20894.
Laura YeeDivision of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), NIH, MD 20894.
Jennifer A CrokerCenter for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL, USA.
Jing WangClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Andrea Lucia AlfonsoSection on Immunoengineering, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda MD 20894.
Mondreakest FaustSection on Immunoengineering, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda MD 20894.
Jennifer MehalkoProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702.
Matthew DrewProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702.
John-Paul DensonProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702.
Zoe PutmanProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702.
Parinaz FathiSection on Immunoengineering, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda MD 20894.
Tran B NgoSection on Immunoengineering, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda MD 20894.
Nalyn SiripongClinical and Translational Science Institute (CTSI), University of Pittsburgh, Pittsburgh, PA 15213.
Holly Ann BausLaboratory of Immunoregulation, NIAID, NIH, Bethesda MD 20894.
Brian PetersenClinical and Translational Science Institute (CTSI), University of Pittsburgh, Pittsburgh, PA 15213.
Eric W FordDepartment of Health Care Organization, and Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.
Vanathi SundaresanSection on Immunoengineering, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda MD 20894.
Aditya JosyulaSection on Immunoengineering, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda MD 20894.
Alison HanLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
Luca T GiurgeaLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
Luz Angela RosasLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
Rachel BeanLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
Rani AthotaLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
Lindsay CzajkowskiLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
Carleen Klumpp-ThomasNational Center for Advancing Translational Sciences (NCATS), NIH, Rockville, MD 20850.
Adriana Cervantes-MedinaLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
Monica GouzoulisLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
Susan ReedLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
Barry GraubardDivision of Cancer Epidemiology & Genetics, Biostatistics Branch, NCI, NIH, Bethesda, MD 20894.
Matthew D HallNational Center for Advancing Translational Sciences (NCATS), NIH, Rockville, MD 20850.
Heather KalishTrans-NIH Shared Resource on Biomedical Engineering and Physical Science (BEPS), NIBIB, NIH, Bethesda MD 20894.
Dominic EspositoProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702.
Robert P KimberlyCenter for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL, USA.
Steven ReisClinical and Translational Science Institute (CTSI), University of Pittsburgh, Pittsburgh, PA 15213.
Kaitlyn SadtlerSection on Immunoengineering, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda MD 20894.
Matthew J MemoliLID Clinical Studies Unit, Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20894.
National Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USProtein Express (United States) · USUniversity of Pittsburgh · USUniversity of Alabama at Birmingham · USNational Center for Advancing Translational Sciences · USDivision of Cancer Epidemiology and GeneticsFrederick National Laboratory for Cancer Research · USNational Cancer Institute · MYUniversity of Maryland, College Park · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
National Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6M
CCR NIH HHS HHSN261200800001CNCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR003096NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Due to a combination of asymptomatic or undiagnosed infections, the proportion of the United States population infected with SARS-CoV-2 was unclear from the beginning of the pandemic. We previously established a platform to screen for SARS-CoV-2 positivity across a representative proportion of the US population, from which we reported that almost 17 million Americans were estimated to have had undocumented infections in the Spring of 2020. Since then, vaccine rollout and prevalence of different SARS-CoV-2 variants have further altered seropositivity trends within the United States population. To explore the longitudinal impacts of the pandemic and vaccine responses on seropositivity, we re-enrolled participants from our baseline study in a 6- and 12- month follow-up study to develop a longitudinal antibody profile capable of representing seropositivity within the United States during a critical period just prior to and during the initiation of vaccine rollout. Initial measurements showed that, since July 2020, seropositivity elevated within this population from 4.8% at baseline to 36.2% and 89.3% at 6 and 12 months, respectively. We also evaluated nucleocapsid seropositivity and compared to spike seropositivity to identify trends in infection versus vaccination relative to baseline. These data serve as a window into a critical timeframe within the COVID-19 pandemic response and serve as a resource that could be used in subsequent respiratory illness outbreaks.

Identifiers

PMID37904956
PMCPMC10614993
OpenAlexW4387861496

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.